¿ Abgenix Inc., of Fremont, Calif., signed a research agreement with BASF Bioresearch Corp., of Worcester, Mass., under which BASF will use Abgenix¿s XenoMouse technology to develop antibodies to an undisclosed antigen target. Abgenix will receive an undisclosed up-front payment and could get milestones and royalties.

¿ Affymetrix Inc., of Santa Clara, Calif., completed a $32.5 million private placement of 1 million shares. The shares were sold to the Growth Fund of America Inc., which is managed by California-based Capital Management and Research Co. (See BioWorld Today, March 17, 1999, p. 1.)